The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

• Type of Material: Article
• Authors: Gary Brown, Emory University; Melissa Brown, Emory University; Heidi B. Lieske, The Center for Value-Based Medicine; Adam Turpcu, The Healthcare Economics Unit, Genentech, Inc.; Yamina Rajput, The Healthcare Economics Unit, Genentech, Inc.
• Language: English
• Date: 2017-12
• Publisher: BioMed Central
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2017
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s40942-016-0058-3
• Title of Journal or Parent Work: International Journal of Retina and Vitreous
• ISSN: 2056-9920
• Volume: 3
• Issue: 1
• Start Page: 5
• End Page: 5
• Keywords: Ranibizumab; Cost-utility analysis; Age-related macular degeneration; Clinical cost-utility model
• Research Categories: Health Sciences, Opthamology; Health Sciences, Rehabilitation and Therapy

Abstract

Background To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of intravitreal ranibizumab therapy for neovascular, age-related macular degeneration (AMD). Methods Value-Based Medicine®, 12-year, combined-eye model, cost-utility analysis employing MARINA and HORIZON clinical trial data. Preference-based comparative effectiveness outcomes were quantified in (1) QALY (quality-adjusted life-year) gain, and (2) percent improvement in quality-of-life, while cost-effectiveness outcomes were quantified in (3) the cost-utility ratio (CUR) and financial return-on-investment (ROI) to society. Results Using MARINA and HORIZON trial data and a meta-analysis control cohort after 24 months, ranibizumab therapy conferred a combined-eye patient value (quality-of-life) gain of 16.3%, versus 10.4% found in 2006. The two-year direct ophthalmic medical cost for ranibizumab therapy was $46,450, a 33.8% real dollar decrease from 2006. The societal cost perspective CUR was −$242,920/QALY, indicating a $282,517 financial return-on-investment (ROI), or 12.3%/year to society for direct ophthalmic medical costs expended. The 3rd party insurer CUR ranged from $21,199/QALY utilizing all direct, medical costs, to $69,591/QALY using direct ophthalmic medical costs. Conclusions Ranibizumab therapy for neovascular AMD in 2015, considering treatment of both eyes, conferred greater patient value gain (comparative effectiveness) and improved cost-effectiveness than in 2006, as well as a large monetary return-on-investment to the Gross Domestic Product and nation’s wealth. The model herein integrates important novel features for neovascular age-related macular degeneration, vitreoretinal cost effectiveness analyses, including: (1) treatment of both eyes, (2) a long-term, untreated control cohort, and (3) the use of societal costs.